MedTrace Logo

Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products.

NCT01227720 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2012-07-10

No results posted yet for this study

Summary

Comparative pharmacokinetic study of new oral nicotine replacement therapy products.

Conditions

  • Tobacco Dependence

Interventions

DRUG

Experimental Nicotine Replacement Therapy (NRT) 2 mg

2 mg Single-dose of new NRT product (NSL2L)

DRUG

Experimental Nicotine Replacement Therapy (NRT)

4 mg Single-dose of new NRT product

DRUG

Marketed Nicotine Lozenge

2 mg Single-dose of marketed lozenge

DRUG

Marketed Nicotine Lozenge

4 mg Single-dose of marketed lozenge

Sponsors & Collaborators

  • McNeil AB

    lead INDUSTRY

Principal Investigators

  • Elisabeth Kruse, PhD · McNeil AB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01227720 on ClinicalTrials.gov